A Phase 4 interventional study of Romosozumab in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 10 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 9th largest by enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 10th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:
Massachusetts General Hospital
Ages 45+ · Women only
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2023.
This study's enrollment of 100 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 268 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 17th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 24th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing romosozumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, from their registry updates:
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be dosed with two subcutaneous (SC) injections of romosozumab once a month for 12 months.
Drug: Romosozumab
Single-use prefilled syringe for SC injection.
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial intervention. If an AE occurred on or after the first dose of trial intervention, the AE was considered to be a TEAE.
Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)
An SAE was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: resulted in death (fatal), was immediately life-threatening, required in-patient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event. A TESAE was defined as an SAE that occurred on or after the first dose of trial intervention.
Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Number of Participants Who Experienced Clinically Significant Changes in Laboratory Assessments
Laboratory parameters included: hematology (red blood cell, hemoglobin, platelets, white blood cell count, neutrophils, eosinophils, monocytes, basophils and lymphocytes), chemistry (sodium, potassium, chloride, bicarbonate, total protein, albumin, calcium, albumin-adjusted calcium, magnesium, phosphorus, glucose, blood urea nitrogen or urea, creatinine, total bilirubin, direct bilirubin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase) and serum 25-hydroxy vitamin D. Clinical significance of laboratory parameters was determined by the investigator.
Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Number of Participants Who Experienced Clinically Significant Changes in Vital Signs
Vital signs included: systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and temperature. Clinical significance of vital signs was determined by the investigator.
Time frame: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6 and Month 12
Lumbar spine BMD was determined by dual-energy X-ray absorptiometry (DXA). Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.
Time frame: Baseline, Month 6 and Month 12
Percent Change From Baseline in Total Hip BMD at Month 6 and Month 12
Total hip BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.
Time frame: Baseline, Month 6 and Month 12
Percent Change From Baseline in Femoral Neck BMD at Month 6 and Month 12
Femoral neck BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.
Time frame: Baseline, Month 6 and Month 12
This trial was conducted at 10 centers in India from October 2023 to October 2025.
| Milestone | Romosozumab 210 mg SC QM |
|---|---|
| Started | 100 |
| Completed | 86 |
| Not completed | 14 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 12 |
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial intervention. If an AE occurred on or after the first dose of trial intervention, the AE was considered to be a TEAE.
| Participants | Romosozumab 210 mg SC QM |
|---|---|
| Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | 73 |
An SAE was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: resulted in death (fatal), was immediately life-threatening, required in-patient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event. A TESAE was defined as an SAE that occurred on or after the first dose of trial intervention.
| Participants | Romosozumab 210 mg SC QM |
|---|---|
| Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs) | 6 |
Laboratory parameters included: hematology (red blood cell, hemoglobin, platelets, white blood cell count, neutrophils, eosinophils, monocytes, basophils and lymphocytes), chemistry (sodium, potassium, chloride, bicarbonate, total protein, albumin, calcium, albumin-adjusted calcium, magnesium, phosphorus, glucose, blood urea nitrogen or urea, creatinine, total bilirubin, direct bilirubin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase) and serum 25-hydroxy vitamin D. Clinical significance of laboratory parameters was determined by the investigator.
| Participants | Romosozumab 210 mg SC QM |
|---|---|
| Number of Participants Who Experienced Clinically Significant Changes in Laboratory Assessments | 0 |
Vital signs included: systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and temperature. Clinical significance of vital signs was determined by the investigator.
| Participants | Romosozumab 210 mg SC QM |
|---|---|
| Number of Participants Who Experienced Clinically Significant Changes in Vital Signs | 0 |
Lumbar spine BMD was determined by dual-energy X-ray absorptiometry (DXA). Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.
| Percent change | Romosozumab 210 mg SC QM |
|---|---|
| Month 6 | 9.2 ± 0.8 |
| Month 12 | 11.1 ± 0.9 |
Total hip BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.
| Percent change | Romosozumab 210 mg SC QM |
|---|---|
| Month 6 | 4.6 ± 0.6 |
| Month 12 | 6.1 ± 0.9 |
Femoral neck BMD was determined by DXA. Baseline was defined as last evaluation prior to or on Study Day 1. If results from baseline DXA were not available, the results from scans taken on or before Study Day 14 were considered as baseline values.
| Percent change | Romosozumab 210 mg SC QM |
|---|---|
| Month 6 | 3.4 ± 0.8 |
| Month 12 | 5.7 ± 1.1 |
Collected over All-cause mortality: From enrollment to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months. For AEs: From first dose of trial intervention to the end of trial; median (min, max) duration was 11.99 (1.02, 13.11) months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romosozumab 210 mg SC QM | 0/100 (0%) | 6/100 (6%) | 47/100 (47%) |
| Event | Romosozumab 210 mg SC QM |
|---|---|
| Myocardial infarctionCardiac disorders | 1/100 |
| CataractEye disorders | 1/100 |
| GastroenteritisInfections and infestations | 1/100 |
| Lower respiratory tract infectionInfections and infestations | 1/100 |
| PneumoniaInfections and infestations | 1/100 |
| Device looseningProduct Issues | 1/100 |
| Event | Romosozumab 210 mg SC QM |
|---|---|
| Injection site painGeneral disorders | 13/100 |
| PruritusSkin and subcutaneous tissue disorders | 9/100 |
| Back painMusculoskeletal and connective tissue disorders | 8/100 |
| AnaemiaBlood and lymphatic system disorders | 7/100 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/100 |
| ConstipationGastrointestinal disorders | 5/100 |
| DyspepsiaGastrointestinal disorders | 5/100 |
| Influenza like illnessGeneral disorders | 5/100 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/100 |
Full Analysis Set (FAS): Included all participants who enrolled in the trial.
| Age, Continuous(Years) | Romosozumab 210 mg SC QM |
|---|---|
| Mean | 63.6 ± 8.9 |
| Sex: Female, Male(Participants) | Romosozumab 210 mg SC QM |
|---|---|
| Female | 100 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Romosozumab 210 mg SC QM |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 100 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Romosozumab 210 mg SC QM |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 100 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2023 to primary completion in Oct 2025, 23 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab
Osteoporosis, Postmenopausal →